Nemus Bioscience, Inc., a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, announced that it has signed an agreement with Pharmaceuticals International Inc. (Pii), a contract development manufacturing organization (CDMO) to develop a sterile eyedrop dosage formulation of NB1111 for human dosing. NB1111 is Nemus’ proprietary prodrug of tetrahydrocannabinol (THC) that is currently undergoing development for the treatment of glaucoma.
Pii is an experienced formulator of ocular-based therapies and we look forward to working with them, and our discovery and research colleagues at the University of Mississippi, to advance a clinical-grade formulation of NB1111 into the clinic. The Company plans to conduct a first-in-human, single-ascending dose clinical trial in Australia among patients with mild to moderate glaucoma
noted Brian Murphy, MD, CEO
and Chief Medical Officer of Nemus.
We look forward to partnering with Nemus to develop an ophthalmic formulation of NB1111 as an improved treatment option for patients with glaucoma. Pii’s extensive product development expertise will be an invaluable contributor to ensuring on-time delivery of the NB1111 formulation for evaluation in the planned clinical trial,
added Dr. Kurt Nielsen,
Pii’s President and CEO.